Stock Research: Sanofi

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Sanofi

PAR:SAN FR0000120578
94
  • Value
    97
  • Growth
    56
  • Safety
    Safety
    61
  • Combined
    80
  • Sentiment
    85
  • 360° View
    360° View
    94
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Sanofi SA is a French healthcare company focused on the research, development, and marketing of therapeutic solutions. It operates in the Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines industries. Sanofi operates globally, with a focus on research and development of therapeutic solutions. In the last fiscal year, the company had a market cap of $118754 million, profits of $32178 million, and revenue of $45849 million, with 84587 employees.

more

ANALYSIS: With an Obermatt 360° View of 94 (better than 94% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Sanofi are very positive. The 360° View is based on consolidating four consolidated indicators, with all four indicators above average for Sanofi. The consolidated Value Rank has an attractive rank of 97, which means that the share price of Sanofi is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 97% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 56, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The company is also safely financed with a Safety rank of 61. Finally, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 85. ...read more

more
Index
EURO STOXX 50
CAC 40
CAC All
SBF 120
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
97 98 99 96
Growth
56 60 51 61
Safety
Safety
61 76 56 27
Sentiment
85 92 44 40
360° View
360° View
94 98 82 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
46 76 45 55
Opinions Change
50 49 47 26
Pro Holdings
n/a 94 86 84
Market Pulse
76 50 19 23
Sentiment
85 92 44 40
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
97 98 99 96
Growth
56 60 51 61
Safety Safety
61 76 56 27
Combined
80 95 90 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
82 50 61 71
Price vs. Earnings (P/E)
60 86 86 87
Price vs. Book (P/B)
87 79 88 78
Dividend Yield
99 94 92 92
Value
97 98 99 96
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
54 61 39 43
Profit Growth
92 50 46 45
Capital Growth
64 55 67 66
Stock Returns
13 77 48 66
Growth
56 60 51 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
46 68 56 47
Refinancing
43 42 43 6
Liquidity
71 73 63 61
Safety Safety
61 76 56 27

Similar Stocks

Discover high‑ranked alternatives to Sanofi and broaden your portfolio horizons.

Michelin

PAR:ML
Country: France
Industry: Tires & Rubber
Size: X-Large
Full Stock Analysis

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Societe Generale

PAR:GLE
Country: France
Industry: Diversified Banks
Size: Medium
Full Stock Analysis

Rubis

PAR:RUI
Country: France
Industry: Gas Utilities
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This is an all-around strong stock. It shows good value, high growth, safe financing, and positive professional sentiment. It is ideal for most buy-and-hold investors who value a good all-around stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: